Pharmacokinetic–pharmacodynamic integration and modelling of oxytetracycline for the calf pathogens Mannheimia haemolytica and Pasteurella multocida
Lees, P; Potter, T; Pelligand, L; Toutain, P L
P L Toutain
A calf tissue cage model was used to study the pharmacokinetics (PK) and pharmacodynamics (PD) of oxytetracycline in serum, inflamed (exudate) and noninflamed (transudate) tissue cage fluids. After intramuscular administration, the PK was characterized by a long mean residence time of 28.3 hr. Based on minimum inhibitory concentrations (MICs) for six isolates each of Mannheimia haemolytica and Pasteurella multocida, measured in serum, integration of in vivo PK and in vitro PD data established area under serum concentration–time curve (AUC0–∞)/MIC ratios of 30.0 and 24.3 hr for M. haemolytica and P. multocida, respectively. Corresponding AUC0–∞/MIC ratios based on MICs in broth were 656 and 745 hr, respectively. PK-PD modelling of in vitro bacterial time–kill curves for oxytetracycline in serum established mean AUC0–24 hr/MIC ratios for 3log10 decrease in bacterial count of 27.5 hr (M. haemolytica) and 60.9 hr (P. multocida). Monte Carlo simulations predicted target attainment rate (TAR) dosages. Based on the potency of oxytetracycline in serum, the predicted 50% TAR single doses required to achieve a bacteriostatic action covering 48-hr periods were 197 mg/kg (M. haemolytica) and 314 mg/kg (P. multocida), respectively, against susceptible populations. Dosages based on the potency of oxytetracycline in broth were 25- and 27-fold lower (7.8 and 11.5 mg/kg) for M. haemolytica and P. multocida, respectively.
Lees, P., Potter, T., Pelligand, L., & Toutain, P. L. (2018). Pharmacokinetic–pharmacodynamic integration and modelling of oxytetracycline for the calf pathogens Mannheimia haemolytica and Pasteurella multocida. Journal of Veterinary Pharmacology and Therapeutics, 41(1), 28-38. https://doi.org/10.1111/jvp.12439
|Journal Article Type||Article|
|Acceptance Date||Jun 12, 2017|
|Publication Date||Feb 1, 2018|
|Deposit Date||Nov 10, 2017|
|Publicly Available Date||Sep 2, 2018|
|Journal||JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS|
|Publisher||American Academy of Veterinary Pharmacology and Therapeutics|
|Peer Reviewed||Peer Reviewed|
You might also like
Pharmacology, safety, efficacy and clinical uses of the COX?2 inhibitor robenacoxib
Levothyrox® new and old formulations: are they switchable for millions of patients?